Although the expression levels of MITF and BRAF across the analysed ROIs—spanning primary tumours, lymph node metastases, and cutaneous metastases—did not show significant differences, the analysis of a gene signature associated with ICI failure29 revealed a notable trend. The gene discussed is MITF; the disease is neoplasm.